News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Amgen Develops Six Cancer Drugs as Anemia Decline Hurts Revenue
April 11, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
April 11 (Bloomberg) -- Amgen Inc., the world's largest biotechnology company by sales, is developing six cancer drugs to help recover from a decline in its anemia products.
Twitter
LinkedIn
Facebook
Email
Print
Preclinical
Amgen
MORE ON THIS TOPIC
Cardiovascular disease
Gossamer Nosedives as Late-Stage Failure Plunges PAH Program Into Uncertainty
February 24, 2026
·
2 min read
·
Tristan Manalac
Weight loss
Novo’s CagriSema Falls to Lilly’s Zepbound in Daring Head-to-Head Test
February 23, 2026
·
4 min read
·
Annalee Armstrong
Insights
Historic ALS Investment Signals New Treatment Momentum
February 23, 2026
·
3 min read
·
Jennifer Smith-Parker
MASH
Beyond Rezdiffra: The 4 Most Promising MASH Pipelines in Play
February 23, 2026
·
6 min read
·
Ben Hargreaves
